Can-Fite reports 10-year survival for liver cancer patient in Namodenoson Phase II study
CANF•Can-Fite reported that a patient with advanced liver cancer in its completed Phase II Namodenoson study has survived for 10 years and remains cancer-free.
1. Patient survival update
Can-Fite said the patient’s complete response had been reported previously; the update follows its announcement of nine-year survival in November 2025. Namodenoson remains in a pivotal Phase III trial for advanced liver cancer patients with underlying cirrhosis, which is still blinded.
